Stansberry Asset Management, LLC Cellectis S.A. Transaction History

Stansberry Asset Management, LLC

  • $721 Million
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2018

Feb 14, 2019
SELL
$15.58 - $28.41 $1.72 Million - $3.13 Million
-110,245 Closed
0 $0
Q3 2018

Nov 14, 2018
BUY
$25.99 - $30.6 $149,910 - $176,500
5,768 Added 5.52%
110,245 $3.11 Million
Q2 2018

Aug 14, 2018
BUY
$27.78 - $38.53 $2.9 Million - $4.03 Million
104,477 New
104,477 $2.96 Million

Others Institutions Holding CLLS

# of Institutions
30
Shares Held
10.8M
Call Options Held
5.9K
Put Options Held
1.4K
View Full List

About Cellectis S.A.

CLLS Quotes by TradingView
  • Ticker CLLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,510,800
  • Market Cap $71M
  • Description
  • Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...
More about CLLS
Track This Portfolio

Track Stansberry Asset Management, LLC Portfolio

Follow Stansberry Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stansberry Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Stansberry Asset Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email